Research progress of surface plasmon resonance technology in drug discovery

doi:10.5246/jcps.2020.07.048

Abstract

Abstract:

Surface plasmon resonance (SPR) technology is a powerful and sensitive tool for investigating molecular interactions. Technical improvements in recent years have brought new functionality to SPR apparatuses that can be widely applied at multiplestages of the drug discovery process. The technology allows users to conduct ligand fishing and offers rich and in-depth information regarding the affinity, specificity, kinetics, concentration and identification of covalent/allosteric/competitive binding behaviors. The present review highlights the principle, sample types, detection ranges, experimental methods, strengths, limitations, and the latest research progress on the application of SPR technology in the drug discovery process.

Key words: Surface plasmon resonance, SPR, Drug discovery, Molecular interaction

CLC Number:

R917

Supporting:

Jing Wang, Qian Wang, Shuxiang Song. Research progress of surface plasmon resonance technology in drug discovery[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(7): 504-513.

References

[1] Zhou, M.; Li, Q.; Wang, R.X. Current experimental methods for characterizing protein-protein interactions. ChemMedChem. 2016, 11, 738-756.

[2] Renaud, J.P.; Chung, C.W.; Helena Danielson, U.; Egner, U.; Hennig, M.; Hubbard, R.E.; Nar, H. Biophysics in drug discovery: impact, challenges and opportunities. Nat. Rev. Drug Discov. 2016, 15, 679.

[3] Ma, W.N.; Yang, L.; He, L.C. Overview of the detection methods for equilibrium dissociation constant KD of drug-receptor interaction. J. Pharm. Anal. 2018, 8, 147-152.

[4] U.S. Pharmacopeia. The United States Pharmacopeial Convention. 2016, USP39, 1272-1288.

[5] The Japanese Pharmacopoeia. Pharmaceutical and Medical Device Regulatory Science Society of Japan. 2016, JP17, 2474-2478.

[6] The Chinese Pharmacopoeia. Chinese Medical Science and Technology Press. 2020, 3429, 339-340.

[7] McDonnell, J.M. Surface plasmon resonance: towards an understanding of the mechanisms of biological molecular recognition. Curr. Opin. Chem. Biol. 2001, 5, 572-577.

[8] Chavanieu, A.; Pugnière, M. Developments in SPR fragment screening. Expert. Opin. Drug Discov. 2016, 11, 489-499.

[9] Patching, S.G. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. Biochim. Biophys. Acta. 2014, 1838, 43-55.

[10] Miura, K. An overview of current methods to confirm protein-protein interactions. Protein Pept. Lett. 2018, 25, 728-733.

[11] Willander, M.; Al-Hilli, S. Analysis of biomolecules using surface plasmons. Micro Nano Technol. Bioanal. 2009, 544, 201-229.

[12] Cai, S.D.; Yan, J.H.; Xiong, H.J.; Liu, Y.F.; Peng, D.M.; Liu, Z.B. Investigations on the interface of nucleic acid aptamers and binding targets. Anal. 2018, 143, 5317-5338.

[13] Genick, C.C.; Wright, S.K. Biophysics: for HTS hit validation, chemical lead optimization, and beyond. Expert. Opin. Drug Discov. 2017, 12, 897-907.

[14] Pang, Y.; Gou, M.; Yang, K.; Lu, J.L.; Han, Y.L.; Teng, H.M.; Li, C.Z.; Wang, H.N.; Liu, C.G.; Zhang, K.J.; Yang, Y.L.; Li, Q.W. Crystal structure of a cytocidal protein from lamprey and its mechanism of action in the selective killing of cancer cells. Cell Commun. Signal. 2019, 17, 54.

[15] Chan, J.F.W.; Yuan, S.F.; Kok, K.H.; To, K.K.W.; Chu, H.; Yang, J.; Xing, F.F.; Liu, J.L.; Yip, C.C.Y.; Poon, R.W.S.; Tsoi, H.W.; Lo, S.K.F.; Chan, K.H.; Poon, V.K.M.; Chan, W.M.; Ip, J.D.; Cai, J.P.; Cheng, V.C.C.; Chen, H.L.; Hui, C.K.M.; Yuen, K.Y. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020, 395, 514-523.

[16] Wrapp, D.; Wang, N.S.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. BioRxiv. 2020, doi:10.1101/2020.02.11.944462.

[17] Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; Chen, H.D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.D.; Liu, M.Q.; Chen, Y.; Shen, X.R.; Wang, X.; Zheng, X.S.; Zhao, K.; Chen, Q.J.; Deng, F.; Liu, L.L.; Yan, B.; Zhan, F.X.; Wang, Y.Y.; Xiao, G.F.; Shi, Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579, 270.

[18] Lan, J.; Ge, J.W.; Yu, J.F.; Shan, S.S.; Zhou, H.; Fan, S.L.; Zhang, Q.; Shi, X.L.; Wang, Q.S.; Zhang, L.Q.; Wang, X.Q. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020, 581, 215-220.

[19] Choi, Y.; Nam, J.; Whitcomb, D.J.; Song, Y.S.; Kim, D.; Jeon, S.; Um, J.W.; Lee, S.G.; Woo, J.; Kwon, S.K.; Li, Y.; Mah, W.; Kim, H.M.; Ko, J.; Cho, K.; Kim, E. SALM5 trans-synaptically interacts with LAR-RPTPs in a splicing-dependent manner to regulate synapse development. Sci. Rep. 2016, 6, 26676.

[20] Lin, Z.H.; Liu, J.M.; Ding, H.D.; Xu, F.; Liu, H.L. Structural basis of SALM5-induced PTPδ dimerization for synaptic differentiation. Nat. Commun. 2018, 9, 268.

[21] Jiao, Q.S.; Wang, R.F.; Jiang, Y.Y.; Liu, B. Study on the interaction between active components from traditional Chinese medicine and plasma proteins. Chem. Central J. 2018, 12, 1-20.

[22] Cao, Y.; Li, Y.H.; Lv, D.Y.; Chen, X.F.; Chen, L.D.; Zhu, Z.Y.; Chai, Y.F.; Zhang, J.P. Identification of a ligand for tumor necrosis factor receptor from Chinese herbs by combination of surface plasmon resonance biosensor and UPLC-MS. Anal. Bioanal. Chem. 2016, 408, 5359-5367.

[23] Xiao, S.L.; Si, L.L.; Tian, Z.Y.; Jiao, P.X.; Fan, Z.B.; Meng, K.; Zhou, X.S.; Wang, H.; Xu, R.Y.; Han, X.; Fu, G.; Zhang, Y.M.; Zhang, L.H.; Zhou, D.M. Pentacyclic triterpenes grafted on CD cores to interfere with influenza virus entry: a dramatic multivalent effect. Biomaterials. 2016, 78, 74-85.

[24] Löfås, S. Optimizing the hit-to-lead process using SPR analysis. Assay Drug Dev. Technol. 2004, 2, 407-415.

[25] Gorgulla, C.; Boeszoermenyi, A.; Wang, Z.F.; Fischer, P.D.; Coote, P.W.; Padmanabha Das, K.M.; Malets, Y.S.; Radchenko, D.S.; Moroz, Y.S.; Scott, D.A.; Fackeldey, K.; Hoffmann, M.; Iavniuk, I.; Wagner, G.; Arthanari, H. An open-source drug discovery platform enables ultra-large virtual screens. Nature. 2020, 580, 663.

[26] Andersson, K.; Karlsson, R.; Löfås, S.; Franklin, G.; Hämäläinen, M.D. Label-free kinetic binding data as a decisive element in drug discovery. Expert. Opin. Drug Discov. 2006, 1, 439-446.

[27] Markgren, P.O.; Schaal, W.; Hämäläinen, M.; Karlén, A.; Hallberg, A.; Samuelsson, B.; Danielson, U.H. Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. J. Med. Chem. 2002, 45, 5430-5439.

[28] Zhang, X.S.; Chen, J.H.; Weng, Z.B.; Li, Q.R.; Zhao, L.; Yu, N.; Deng, L.; Xu, W.; Yang, Y.; Zhu, Z.P.; Huang, H.M. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action. Mol. Immunol. 2020, 119, 48-58.

[29] Ditto, N.T.; Brooks, B.D. The emerging role of biosensor-based epitope binning and mapping in antibody-based drug discovery. Expert. Opin. Drug Discov. 2016, 11, 925-937.

[30] Jung, S.K.; Lee, K.H.; Jeon, J.W.; Lee, J.W.; Kwon, B.O.; Kim, Y.J.; Bae, J.S.; Kim, D.I.; Lee, S.Y.; Chang, S.J. Physicochemical characterization of Remsima. mAbs. 2014, 6, 1163-1177.

[31] Chen, L.X.; Wang, L.; Shion, H.; Yu, C.F.; Yu, Y.Q.; Zhu, L.; Li, M.; Chen, W.B.; Gao, K. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. mAbs. 2016, 8, 1210-1223.

[32] Danho, W.; Swistok, J.; Khan, W.; Chu, X.J.; Cheung, A.; Fry, D.; Sun, H.; Kurylko, G.; Rumennik, L.; Cefalu, J.; Cefalu, G.; Nunn, P. Opportunities and challenges of developing peptide drugs in the pharmaceutical industry. Adv. Exp. Med. Biol. 2009, 611, 467-469.

[33] Diao, L.; Meibohm, B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin. Pharmacokinet. 2013, 52, 855-868.

[34] Pan, H.C.; Xie, Y.N.; Lu, W.Y.; Chen, Y.; Lu, Z.; Zhen, J.; Wang, W.W.; Shang, A.Q. Engineering an enhanced thrombin-based GLP-1 analog with long-lasting glucose-lowering and efficient weight reduction. RSC Adv. 2019, 9, 30707-30714.

[35] Yang, G.R.; Zhao, X.L.; Jin, F.; Shi, L.H.; Yang, J.K. Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes. J. Clin. Pharmacol. 2015, 55, 152-158.

[36] Kroenke, M.A.; Weeraratne, D.K.; Deng, H.J.; Sloey, B.; Subramanian, R.; Wu, B.; Serenko, M.; Hock, M.B. Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments. J. Immunol. Methods. 2017, 445, 37-44.

[37] Shibata, H.; Nishimura, K.; Miyama, C.; Tada, M.; Suzuki, T.; Saito, Y.; Ishii-Watabe, A. Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes. J. Immunol. Methods. 2018, 452, 73-77.

[38] Gassner, C.; Lipsmeier, F.; Metzger, P.; Beck, H.; Schnueriger, A.; Regula, J.T.; Moelleken, J. Development and validation of a novel SPR-based assay principle for bispecific molecules. J. Pharm. Biomed. Anal. 2015, 102, 144-149.

[39] Ma, G.Z.; Syu, G.D.; Shan, X.N.; Henson, B.; Wang, S.P.; Desai, P.J.; Zhu, H.; Tao, N.J. Measuring ligand binding kinetics to membrane proteins using virion nano-oscillators. J. Am. Chem. Soc. 2018, 140, 11495-11501.

[40] Zhao, S.; Yang, M.; Zhou, W.F.; Zhang, B.C.; Cheng, Z.Q.; Huang, J.X.; Zhang, M.; Wang, Z.Y.; Wang, R.; Chen, Z.L.; Zhu, J.S.; Li, H.T. Kinetic and high-throughput profiling of epigenetic interactions by 3D-carbene chip-based surface plasmon resonance imaging technology. Proc. Natl. Acad. Sci. USA. 2017, 114, E7245-E7254.